CROSSJECT (FRA:74C) Gross Margin %: 0.00% (As of Dec. 2025)


FRA:74C CROSSJECT FRA:74C
42 GF Score
Price €1.72
GF Value €1.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CROSSJECT Gross Margin %?

CROSSJECT FRA:74C -1.60% 42 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates FRA:74C with a GF Score™ of 42/100 and a GF Value™ of €1.13 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, CROSSJECT ranks worse than 124223.48% on this metric.

Gross Margin % is calculated as gross profit divided by its revenue. CROSSJECT's Gross Profit for the six months ended in Dec. 2025 was €-5.16 Mil. CROSSJECT's Revenue for the six months ended in Dec. 2025 was €0.00 Mil. Therefore, CROSSJECT's Gross Margin % for the quarter that ended in Dec. 2025 was 0.00%.


The historical rank and industry rank for CROSSJECT's Gross Margin % or its related term are showing as below:


During the past 13 years, the highest Gross Margin % of CROSSJECT was -42.76%. The lowest was -4231.03%. And the median was -257.81%.

FRA:74C's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 51.94
* Ranked among companies with meaningful Gross Margin % only.

CROSSJECT had a gross margin of % for the quarter that ended in Dec. 2025 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for CROSSJECT was 0.00% per year.


CROSSJECT  (FRA:74C) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CROSSJECT had a gross margin of % for the quarter that ended in Dec. 2025 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


CROSSJECT Gross Margin % Related Terms


CROSSJECT Gross Margin % Historical Data

* Premium members only.

The historical data trend for CROSSJECT's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CROSSJECT Gross Margin % Chart

CROSSJECT Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.76 -126.42 -4,231.03 0.00 0.00

CROSSJECT Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,893.79 0.00 0.00 0.00 0.00

FRA:74C vs ISRG, BDX, MDLN: Gross Margin % Comparison

For the Medical Instruments & Supplies subindustry, CROSSJECT's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CROSSJECT Gross Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CROSSJECT's Gross Margin % distribution charts can be found below:

* The bar in red indicates where CROSSJECT's Gross Margin % falls into.


FRA:74C
42GF Score
CROSSJECT FRA:74C
Gross Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CROSSJECT Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

CROSSJECT's Gross Margin for the fiscal year that ended in Dec. 2025 is calculated as

Gross Margin % (A: Dec. 2025 )=Gross Profit (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-9.7 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 9.713) / 0
= %

CROSSJECT's Gross Margin for the quarter that ended in Dec. 2025 is calculated as


Gross Margin % (Q: Dec. 2025 )=Gross Profit (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-5.2 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 5.158) / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
CROSSJECT (FRA:74C) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CROSSJECT and its competitors. According to the industry distribution chart, CROSSJECT ranks #999999 out of 805 companies in the Medical Devices & Instruments industry.
Is CROSSJECT's Gross Margin % too high?
CROSSJECT's current Gross Margin % is 0.00%. Based on the distribution chart, CROSSJECT ranks #999999 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CROSSJECT has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CROSSJECT's Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, CROSSJECT ranks #999999 out of 805 companies for Gross Margin %. This places CROSSJECT in the lower half of its industry. The industry median Gross Margin % is 51.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CROSSJECT and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CROSSJECT's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CROSSJECT stock overvalued right now?
Based on GuruFocus' analysis, CROSSJECT (FRA:74C) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.13, compared to a current price of €1.72 — trading 52% above its estimated fair value. The current Gross Margin % is 0.00%. CROSSJECT's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CROSSJECT (FRA:74C), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CROSSJECT (FRA:74C) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.72 is trading 52% above its estimated GF Value™ of €1.13. GuruFocus considers CROSSJECT to be Significantly Overvalued.

Key valuation signals for FRA:74C:

  • Gross Margin %: 0.00%
  • GF Value™: €1.13 vs. price of €1.72 (52% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:74C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CROSSJECT Business Description

Other Exchanges ALCJ:France74C:Germany
Address 60L avenue du 14 Juillet, Chenôve, FRA, 21300
CROSSJECT manufactures and markets needle-free drug self-injection system.
42GF Score

Get the complete analysis for FRA:74C

Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.72
Price
€1.13
GF Value